心瑋醫療-B(06609.HK)擬3480萬元攬入御瓣醫療科技44.96%股權 完善心臟介入治療領域佈局
心瑋醫療-B(06609.HK)宣佈，於2022年2月8日，公司全資附屬公司瑋啟醫療、賣方(張豔霞及李俊)、目標公司(上海御瓣醫療科技有限公司)及目標股東(Li Feng及萍鄉榕嘉寳商務諮詢合夥企業(有限合夥))訂立收購及注資協議，據此，瑋啟醫療同意收購目標公司的36%股權，代價為人民幣480萬元，及瑋啟醫療同意向目標公司注資人民幣3000萬元，以換取目標公司的註冊資本人民幣542,636元。
於收購及注資完成後，瑋啟醫療將持有目標公司44.96%的股份。收購及注資將以集團的內部資源而非以公司全球發售募集的所得款項撥付。
據悉，目標公司為一家醫療器械開發商，致力於為結構性心臟病制定最佳解決方案。目前，目標公司旨在透過內部研發豐富其多維管線，成為二尖瓣返流及三尖瓣返流以及二尖瓣置換方面的領先企業。迄今為止，目標公司的二尖瓣修復產品已開始臨牀試驗，三尖瓣修復產品已進入動物試驗階段。
董事會認為，收購將為公司帶來長期及戰略利益。收購符合集團將其產品覆蓋面擴大至結構性心臟病治療領域的戰略，並加強公司在心臟介入治療領域的治療方案。其將與公司的心臟栓塞性中風預防和電生理產品線形成協同效應。總之，收購將使公司的產品組合多樣化，減少對其現有神經幹預管線產品的依賴，並提升公司在中國創新醫療器械市場的領導地位。
此外，由於目標公司的研發需求及其產品規模的擴大需要投入資金。注資旨在增加目標公司的註冊資本，以為其發展計劃的實施及執行提供資金，實現其增長機會。具體而言，目標公司的管線產品正處於開發階段，需要進一步測試及臨牀試驗。注資將加速其內部研發進程。
作為國內神經介入醫療器械的頭部企業，集團已在中國神經介入市場確立了先鋒領導地位，併成功地提供了國內首創及獨有的中風治療和預防的一站式解決方案。基於集團的先發優勢，集團將繼續專注於創新技術的普及，通過滿足中國臨牀醫生和患者未被滿足的需求，同時經營從神經介入、電生理、肺部介入至計算機輔助手術等各種新興業務單元。
在上述具有巨大商機的治療領域和醫療市場，集團旨在通過不斷推出創新的醫療器械，重新定義護理標準，降低死亡率，改善預後。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
